REGN Stock Summary and Trading Ideas (Regeneron Pharmaceuticals | NASDAQ:REGN)

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Regeneron Pharmaceuticals trades on the NASDAQ stock market under the symbol REGN.

As of May 12, 2026, REGN stock price climbed to $723.41 with 779,217 million shares trading.

REGN has a beta of 0.46, meaning it tends to be less sensitive to market movements. REGN has a correlation of 0.02 to the broad based SPY ETF.

REGN has a market cap of $75.84 billion. This is considered a Large Cap stock.

Last quarter Regeneron Pharmaceuticals reported $4 billion in Revenue and $9.47 earnings per share. This beat revenue expectation by $130 million and exceeded earnings estimates by $1.09.

In the last 3 years, REGN traded as high as $1,211.20 and as low as $476.49.

The top ETF exchange traded funds that REGN belongs to (by Net Assets): VTI, VOO, QQQ, IVV, SPY.

REGN has outperformed the market in the last year with a return of +37.7%, while the SPY ETF gained +32.1%. However, in the most recent history, REGN shares have underperformed the stock market with its stock returning -7.0% in the last 3 month period and -2.8% for the last 2 week period, while SPY has returned +6.9% and +3.2%, respectively.

REGN support price is $701.39 and resistance is $724.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that REGN shares will trade within this expected range on the day.